Table 2.

Induction of Immune Responses and Protection Against VEEV TrD Challenges in Mice Immunized with gV3526 Formulations

Vaccine Formulation	Route of Vaccination	Dosaged (µg/dosage)	Percent Seroconversiona PRN
			Day 21 Post- vaccinationb	Day 49 Post- vaccinationb
gV3526	SC	0.2	35	85
gV3526	IM IM	0.02 0.04e	0 30	40 80
gV3526/ CpG	SC	0.2	35	75
gV3526/ CpG	IM IM	0.02 0.04e	10 30	55 78c
gV3526/ AlOH	SC	0.2	55	90
gV3526/ AlOH	IM IM	0.02 0.04e	20 50	60 90
gV3526 / CpG + AlOH	IM	0.04e	60	100
C-84 (3 dosage)	SC	4	60	100
CpG alone AlOH alone CpG + AlOH alone	SC and IM SC and IM SC and IM	0 0 0	0 0 0	0 0 0
Saline	SC IM	0 0	0 0	0 0

^aPercent seroconversion is defined as follows: PRNT, the percentage of mice with PRN titers ≥20; ELISA, the percentage of mice with ELISA titers ≥100.

^bPercent seroconversion was calculated by combining groups of similarly vaccinated mice making a total of 20 mice per group. Groups were later split into 10 mice challenged by the aerosol route and 10 challenged by the SC route.

^cThe total number of mice in this group was 19 at the time of the 49 day blood draw. One mouse succumbed to a non-study related reason between study day 21 and 49.

^dAll dosages were administered on a 2 dose schedule (day 0 and 28) except for C-84 which was administered on a 3 dose schedule (day 0, 7 and 28).

^eTo double the IM dosage, both hind limb muscles were injected with 0.05 mL of inoculum (0.02 µg gV3526).